Status:

COMPLETED

Oxidative Stress in Patients With Age-Related Macular Degeneration

Lead Sponsor:

University Hospital, Basel, Switzerland

Conditions:

Macular Degeneration

Eligibility:

All Genders

50-85 years

Brief Summary

First, to quantify, by means of comet assay analysis, systemic oxidative stress in patients with non-exudative and exudative age-related macular degeneration (AMD) and compare results to healthy contr...

Detailed Description

Oxidative stress is the major factor that plays a role in the pathogenesis of age-related macular degeneration (AMD), which is a leading cause of blind registration in the developed world. The term ox...

Eligibility Criteria

Inclusion

  • For patients with dry non- exudative AMD:
  • Patients between the ages of 50 and 85 yr inclusive.
  • Study eye must have a diagnosis of nonexudative "dry" AMD with ≥10 large soft, semisoft, and/or confluent drusen within 3,000 nm of the foveal center.
  • Study eye must have a best corrected visual acuity using the ETDRS chart between 0.1 patem and 0.8 patem inclusive.
  • Geographic atrophy is allowed as long as it is less than 3 disc diameters within 3,000 nm of the foveal center.
  • Study eye must not have conditions that limit the view of the fundus.
  • For patients with exudative AMD with clinical indication for PDT treatment:
  • Patients between the ages of 50 and 85 yrs with exudative AMD with clinical indication for PDT treatment.
  • Primary or recurrent subfoveal CNV due to AMD
  • Central 1-mm retinal thickness (optical coherence tomography) \> 300 um
  • Best-corrected visual acuity, using ETDRS charts, of \> 0.05patem
  • Evidence of recent disease progression, including the loss of at least 1 line of visual acuity or macular hemorrhage within the previous 12 wks.
  • For healthy subjects:
  • An intraocular pressure \< 20 mmHg
  • Normal blood pressure (100-140/60-90mm Hg)
  • Best corrected visual acuity, using EDTRS charts of above 0.6 patem in both eyes
  • No pathological findings upon slit-lamp examination and indirect fundoscopy

Exclusion

  • History of other ocular or systemic disease
  • History of chronic or current systemic or topical medication, or of significant drug or alcohol abuse(significant is defined as that which may influence results of the study
  • History of ocular trauma or intraocular surgery within the past 6 months
  • History of infection or inflammation within the past 3 months

Key Trial Info

Start Date :

November 1 2006

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2007

Estimated Enrollment :

12 Patients enrolled

Trial Details

Trial ID

NCT00465400

Start Date

November 1 2006

End Date

December 1 2007

Last Update

December 9 2008

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Eye Clinic Basel

Basel, Canton of Basel-City, Switzerland, 4031